Tirzepatide is a first-in-class dual GIP and GLP-1 receptor agonist developed by Eli Lilly, FDA-approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound) including severe obstructive sleep apnea in adults with obesity. It is a 39-amino-acid peptide with a C20 fatty di-acid moiety that promotes albumin binding, enabling once-weekly dosing. Clinical trials consistently demonstrate it delivers the most substantial weight reduction among incretin-based therapies, with up to 22.5% mean body weight loss at 72 weeks.
Category: Metabolic / Dual GIP-GLP-1 Agonist. Evidence rating: A (strong human clinical data).
Clinical status: FDA-approved (Mounjaro for T2D, Zepbound for obesity and OSA)
Tirzepatide (MW ~4813 g/mol, C225H348N48O68) simultaneously activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. This dual agonism enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, increases…
Research base: 251 registered clinical trials and 187 indexed publications reference Tirzepatide.
Safety considerations: Common (5%+ in trials): abdominal pain, burping, constipation, diarrhea, dyspepsia, fatigue, GERD, hair loss, hypersensitivity reactions, injection site reactions, nausea, vomiting; Serious but rare: pancreatitis, gallbladder events, dehydration leading to kidney problems; FDA boxed warning for thyroid C-cell tumors (rodent data); call doctor for neck lump, swallowing difficulty, hoarseness, or shortness of breath.
Reviewed by the PeptideAtlas Editorial Team. Last reviewed: 2026-07-05.
The SURMOUNT-5 head-to-head trial (NCT05822830) showed 47% greater weight loss with tirzepatide compared to semaglutide over 72 weeks at maximum tolerated doses. Tirzepatide patients lost an average of 20.9% body weight vs 13.7% with semaglutide. However, individual responses vary and the choice depends on clinical context, insurance coverage, and side effect tolerance.
Switching should only be done under medical supervision. Dose titration protocols differ between the two medications.
Tirzepatide starts at 2.5 mg subcutaneously once weekly for 4 weeks, then increases to 5 mg. Further increases in 2.5 mg increments every 4+ weeks up to a maximum of 15 mg weekly. Available as single-dose pens in 2.5, 5, 7.5, 10, 12.5, and 15 mg strengths.
Appetite and craving changes begin in the first 4 weeks. Measurable weight loss occurs at 2-3 months, increasing over 6-12 months. In SURMOUNT-1, patients on 15 mg lost an average of 22.5% body weight over 72 weeks.
If within 4 days of the missed dose, take it as soon as remembered. If more than 4 days have passed, skip and continue the regular schedule. Do not inject two doses within 3 days of each other.